🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Validity and Reliability of the Figure-of-Eight Walking and Weight-Bearing Lunge Tests in Hemophilia

Recruitingn/aAges 18 Years - 65 YearsMaleYuzuncu Yil University
NCT07851922 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Recurrent joint bleeding (hemarthrosis) occurs in 70-80% of cases of hemophilia. The three most frequently affected joints are the synovial joints of the ankle, knee, and elbow. Among these, the ankle and knee are the most common sites of bleeding, accounting for 80% of cases (Stephensen et al., 2009). This susceptibility stems from factors such as the fact that the knee and ankle are weight-bearing joints and are highly exposed to trauma. Hemophilia treatment aims to reduce the frequency of bleeding episodes through prophylactic factor replacement; however, joint bleeding can recur despite treatment, potentially leading to permanent joint damage. This joint disease causes pain, reduced range of motion, and potential impairment of postural balance, while also increasing the risk of falls. Due to its complexity and significance for the individual, gait assessment is a crucial component

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * a diagnosis of hemophilia A * severe, moderate or mild clinical severity of hemophilia * a history of bleeding in at least one knee or ankle joint * being aged 18-65 * the ability to walk 20 meters independently without a cane or crutches Exclusion Criteria: * inability to stand unsupported; presence of an orthopaedic, neurological, and/or psychiatric condition affecting balance or physical performance * visual impairment * inhibitor positivity * inability to bear weight through the lower extremities * major lower-extremity surgery within the previous 6 months * haemarthrosis within the previous 2 weeks.
💊

What it tests

  • Not listed
📍

Where

1 site
Van Yuzuncu Yil University
Van, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy